{"id":133424,"date":"2022-08-23T07:08:55","date_gmt":"2022-08-23T11:08:55","guid":{"rendered":"https:\/\/44.250.171.167\/?p=133424"},"modified":"2022-10-06T04:45:54","modified_gmt":"2022-10-06T08:45:54","slug":"supriya-lifescience-ltd-q1-fy23-earnings-conference-call-insights","status":"publish","type":"post","link":"https:\/\/alphastreet.com\/india\/supriya-lifescience-ltd-q1-fy23-earnings-conference-call-insights\/","title":{"rendered":"Supriya Lifescience Ltd Q1 FY23 Earnings Conference Call Insights"},"content":{"rendered":"<p><iframe loading=\"lazy\" title=\"Supriya Lifescience Ltd Q1 FY23 Earnings Concall\" width=\"500\" height=\"375\" src=\"https:\/\/www.youtube.com\/embed\/LNBcyeiXX0U?feature=oembed\" frameborder=\"0\" allow=\"accelerometer; autoplay; clipboard-write; encrypted-media; gyroscope; picture-in-picture; web-share\" referrerpolicy=\"strict-origin-when-cross-origin\" allowfullscreen><\/iframe><\/p>\n<p><strong>Key highlights from Supriya Lifescience Ltd (<a href=\"https:\/\/44.250.171.167\/symbol\/SUPRIYA\/\">SUPRIYA<\/a>) Q1 FY23 Earnings Concall<\/strong><\/p>\n<p><strong>Management Update:<\/strong><\/p>\n<ul>\n<li>SUPRIYA said the company is extending its backward integration model to its new products to maintain the competitive edge. The company added that a larger part of the growth and sustainability will be driven by the backward integrated products.<\/li>\n<\/ul>\n<p><strong>Q&amp;A Highlights:<\/strong><\/p>\n<ul>\n<li>Dhaval Shah of Girik Capital asked about Block 4 revenue contribution to total revenue in 1Q23. Satish Wagh Chairman said that company\u2019s 4 blocks are interconnected, so it\u2019s impossible to identify how much revenue is generated from a particular block.<\/li>\n<\/ul>\n<ul>\n<li>Dhaval Shah of Girik Capital asked that given the current expansion, if it\u2019s safe to assume that SUPRIYA will be around INR1,000 crore sales by 2025 on an 810 kl capacity. Satish Wagh Chairman replied that going ahead the company is looking at an asset turnover of about 3 because of the new capacities that are going to come up.<\/li>\n<\/ul>\n<ul>\n<li>Dhaval Shah of Girik Capital enquired if the company would be able to show growth in 2Q23 over 2Q22 EBITDA margin of 53% on INR150 crore topline. Satish Wagh Chairman said the company cannot comment on quarterly targets, but for FY23 SUPRIYA will be doing very good and margins will be at a healthy rate.<\/li>\n<\/ul>\n<ul>\n<li>Keshav Kumar with RakSan Investors asked what\u2019s been the change in per kg prices for acetaminophen. \u00a0Satish Wagh Chairman replied that as of now these are stable over the last few years and the growth has come largely due to volumes.<\/li>\n<\/ul>\n<ul>\n<li>Nishant Sabnis from Sabnis Financial asked about the margin profile going forward since RM prices have subsided a bit. Satish Wagh Chairman answered that almost 70% of the revenue is generated for backward integrated products. As such there has not been any major impact on the costing for the products.<\/li>\n<\/ul>\n<ul>\n<li>Yogesh Tiwari asked about the drivers of Asia revenue declining. \u00a0Satish Wagh Chairman replied that it is a factor of the product mix which is a seasonal thing. Some of the products do well in some quarters and there has also been some impact due to China lockdown.<\/li>\n<\/ul>\n<ul>\n<li>Siddharth Purohit from InvesQ Investment asked about other costs being higher in the quarter. Satish Wagh Chairman said that the power cost has contributed to the other cost going up. Power costs increased in the recent past. Going ahead, SUPRIYA doesn\u2019t expect any major spike till the next two blocks are operational.<\/li>\n<\/ul>\n","protected":false},"excerpt":{"rendered":"<p>Key highlights from Supriya Lifescience Ltd (SUPRIYA) Q1 FY23 Earnings Concall Management Update: SUPRIYA said the company is extending its backward integration model to its new products to maintain the competitive edge. The company added that a larger part of the growth and sustainability will be driven by the backward integrated products. Q&amp;A Highlights: Dhaval [&hellip;]<\/p>\n","protected":false},"author":1767,"featured_media":125416,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"jetpack_post_was_ever_published":false,"footnotes":"","jetpack_publicize_message":"Supriya Lifescience Ltd Q1 FY23 Earnings Conference Call Insights #SUPRIYA #Q1 #FY23 #Earnings","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[9825,392,5747],"tags":[1115],"class_list":["post-133424","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-earnings-call-highlights","category-earnings","category-healthcare-stocks","tag-pharmaceuticals"],"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/alphastreet.com\/india\/wp-content\/uploads\/2021\/11\/Earnings-Coverage.jpg","jetpack_likes_enabled":false,"jetpack-related-posts":[{"id":170225,"url":"https:\/\/alphastreet.com\/india\/supriya-lifescience-q1-fy26-earnings-results\/","url_meta":{"origin":133424,"position":0},"title":"Supriya Lifescience Q1 FY26 Earnings Results\u00a0","author":"Chirag Gupta","date":"August 15, 2025","format":false,"excerpt":"Supriya Lifescience is engaged in the manufacturing of Active pharmaceutical ingredients (APIs). As of March 31, 2021, the company produces 38 APIs focused on diverse therapeutic segments such as antihistamine, analgesic, anaesthetic, vitamin, anti-asthmatic and anti-allergic. Syntec Do Brasil LTDA, American International Chemical Inc. and AT Planejamento E Desenvolvimento De\u2026","rel":"","context":"In &quot;AlphaGraphs&quot;","block_context":{"text":"AlphaGraphs","link":"https:\/\/alphastreet.com\/india\/category\/infographics\/"},"img":{"alt_text":"Supriya Lifescience Q1 FY26 Earnings Results","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/08\/4-10.png?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/08\/4-10.png?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/08\/4-10.png?resize=525%2C300&ssl=1 1.5x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/08\/4-10.png?resize=700%2C400&ssl=1 2x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/08\/4-10.png?resize=1050%2C600&ssl=1 3x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/08\/4-10.png?resize=1400%2C800&ssl=1 4x"},"classes":[]},{"id":129979,"url":"https:\/\/alphastreet.com\/india\/supriya-lifescience-ltd-q4-fy22-earnings-conference-call-insights\/","url_meta":{"origin":133424,"position":1},"title":"Supriya Lifescience Ltd Q4 FY22 Earnings Conference Call Insights","author":"Praveen","date":"May 24, 2022","format":false,"excerpt":"https:\/\/youtu.be\/VIL70Aj2g04 Key highlights from Supriya Lifescience Ltd (SUPRIYA) Q4 FY22 Earnings Concall Management Update: SUPRIYA said that going forward the company\u2019s focus would be on improving its infrastructure, which includes debottlenecking of its capacity and developing new manufacturing blocks. Q&A Highlights: Naresh Vaswani of Sameeksha Capital asked about the reason\u2026","rel":"","context":"In &quot;Concall Highlights&quot;","block_context":{"text":"Concall Highlights","link":"https:\/\/alphastreet.com\/india\/category\/earnings-call-highlights\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2021\/11\/Earnings-Coverage.jpg?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2021\/11\/Earnings-Coverage.jpg?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2021\/11\/Earnings-Coverage.jpg?resize=525%2C300&ssl=1 1.5x"},"classes":[]},{"id":143220,"url":"https:\/\/alphastreet.com\/india\/supriya-lifescience-ltd-q3-fy23-earnings-conference-call-insights\/","url_meta":{"origin":133424,"position":2},"title":"Supriya Lifescience Ltd Q3 FY23 Earnings Conference Call Insights","author":"Praveen","date":"March 9, 2023","format":false,"excerpt":"Key highlights from Supriya Lifescience Ltd (SUPRIYA) Q3 FY23 Earnings Concall Management Update: [00:04:00] SUPRIYA said its primary focus remains on expanding its regulatory market presence with new emerging markets, backward integration and manufacturing capacity optimization. [00:05:45] SUPRIYA had a challenging quarter due to the extended lockdowns and widespread use\u2026","rel":"","context":"In &quot;Concall Highlights&quot;","block_context":{"text":"Concall Highlights","link":"https:\/\/alphastreet.com\/india\/category\/earnings-call-highlights\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2021\/11\/Earnings-Coverage.jpg?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2021\/11\/Earnings-Coverage.jpg?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2021\/11\/Earnings-Coverage.jpg?resize=525%2C300&ssl=1 1.5x"},"classes":[]},{"id":151121,"url":"https:\/\/alphastreet.com\/india\/supriya-lifescience-ltd-q1fy24-16-rise-in-profits\/","url_meta":{"origin":133424,"position":3},"title":"Supriya Lifescience Ltd Q1FY24; 16% rise in Profits","author":"Chirag Gupta","date":"August 3, 2023","format":false,"excerpt":"Supriya Lifescience is engaged in the manufacturing of Active pharmaceutical ingredients (APIs). As of March 31, 2021, the company produces 38 APIs focused on diverse therapeutic segments such as antihistamine, analgesic, anaesthetic, vitamin, anti-asthmatic and anti-allergic. Financial Results: Supriya Lifescience Ltd reported Revenues for Q1FY24 of \u20b9132.00 Crores up from\u2026","rel":"","context":"In &quot;AlphaGraphs&quot;","block_context":{"text":"AlphaGraphs","link":"https:\/\/alphastreet.com\/india\/category\/infographics\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/08\/image-150.png?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/08\/image-150.png?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/08\/image-150.png?resize=525%2C300&ssl=1 1.5x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/08\/image-150.png?resize=700%2C400&ssl=1 2x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/08\/image-150.png?resize=1050%2C600&ssl=1 3x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/08\/image-150.png?resize=1400%2C800&ssl=1 4x"},"classes":[]},{"id":164722,"url":"https:\/\/alphastreet.com\/india\/supriya-lifescience-ltd-q1fy24-16-rise-in-profits-2\/","url_meta":{"origin":133424,"position":4},"title":"Supriya Lifescience Ltd Q1FY24; 16% rise in Profits","author":"Chirag Gupta","date":"October 7, 2024","format":false,"excerpt":"Supriya Lifescience is engaged in the manufacturing of Active pharmaceutical ingredients (APIs). As of March 31, 2021, the company produces 38 APIs focused on diverse therapeutic segments such as antihistamine, analgesic, anaesthetic, vitamin, anti-asthmatic and anti-allergic. Financial Results: Supriya Lifescience Ltd reported Revenues for Q1FY24 of \u20b9132.00 Crores up from\u2026","rel":"","context":"In &quot;AlphaGraphs&quot;","block_context":{"text":"AlphaGraphs","link":"https:\/\/alphastreet.com\/india\/category\/infographics\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2024\/10\/image-36.png?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2024\/10\/image-36.png?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2024\/10\/image-36.png?resize=525%2C300&ssl=1 1.5x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2024\/10\/image-36.png?resize=700%2C400&ssl=1 2x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2024\/10\/image-36.png?resize=1050%2C600&ssl=1 3x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2024\/10\/image-36.png?resize=1400%2C800&ssl=1 4x"},"classes":[]},{"id":155892,"url":"https:\/\/alphastreet.com\/india\/supriya-lifescience-ltd-q2fy24-41-rise-in-profits\/","url_meta":{"origin":133424,"position":5},"title":"Supriya Lifescience Ltd Q2FY24; 41% rise in Profits","author":"Chirag Gupta","date":"November 7, 2023","format":false,"excerpt":"Supriya Lifescience is engaged in the manufacturing of Active pharmaceutical ingredients (APIs). As of March 31, 2021, the company produces 38 APIs focused on diverse therapeutic segments such as antihistamine, analgesic, anaesthetic, vitamin, anti-asthmatic and anti-allergic. Financial Results: Supriya Lifescience Ltd reported Revenues for Q2FY24 of \u20b9140.00 Crores up from\u2026","rel":"","context":"In &quot;AlphaGraphs&quot;","block_context":{"text":"AlphaGraphs","link":"https:\/\/alphastreet.com\/india\/category\/infographics\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/11\/image-93.png?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/11\/image-93.png?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/11\/image-93.png?resize=525%2C300&ssl=1 1.5x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/11\/image-93.png?resize=700%2C400&ssl=1 2x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/11\/image-93.png?resize=1050%2C600&ssl=1 3x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/11\/image-93.png?resize=1400%2C800&ssl=1 4x"},"classes":[]}],"jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/posts\/133424","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/users\/1767"}],"replies":[{"embeddable":true,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/comments?post=133424"}],"version-history":[{"count":0,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/posts\/133424\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/media\/125416"}],"wp:attachment":[{"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/media?parent=133424"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/categories?post=133424"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/tags?post=133424"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}